Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Renee Keenan

Nurse Practitioner, Gerontology Abington, PA Nurse Practitioner

NPI 1407215569 CMS profile 10904678

1200 Old York Rd, Abington, PA 19001

Open in the dashboard

General payments

$5,516

188 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Renee Keenan of Abington, PA is reported in the CMS Open Payments database as having received $5,516 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,619 70
2024 General $1,707 56
2023 General $699 37
2022 General $438 22
2021 General $53 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Renee Keenan
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Renee Keenan were reported at $2,619. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Renee Keenan Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $53 $133 $44–$396 $132
2022 $438 $142 $48–$452 $149
2023 $699 $158 $53–$482 $160
2024 $1,707 $171 $55–$533 $164
2025 $2,619 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,467 30 payments
  2. Novartis Pharmaceuticals Corporation $549 34 payments
  3. AstraZeneca Pharmaceuticals LP $541 15 payments
  4. Atricure, Inc. $363 11 payments
  5. Pfizer Inc. $317 16 payments
  6. BridgeBio Pharma, Inc. $270 4 payments
  7. Alnylam Pharmaceuticals Inc. $256 7 payments
  8. Merck Sharp & Dohme Corporation $244 9 payments
  9. E.R. Squibb & Sons, L.L.C. $236 10 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $229 13 payments
  11. Other $1,043 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,516 188 payments
Products named General payments · program years 2021–2025
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Structural Heart $761 10 payments
  2. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Heart failure $508 11 payments
  3. WAINUA $435 9 payments
  4. VYNDAQEL $302 15 payments
  5. LEQVIO $299 17 payments
  6. VERQUVO $285 11 payments
  7. Attruby $270 4 payments
  8. CAMZYOS $236 10 payments
  9. LifeVest $229 13 payments
  10. ATRICLIP LAA EXCLUSION SYSTEM $175 6 payments
  11. Other $2,335 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

471

Median for Nurse Practitioner: 389

Drug cost

$1,261,949

Median for Nurse Practitioner: $21,885

Branded share of claims

29.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 30 $807,917
Camzyos Mavacamten Brand 39 $343,207
Entresto Sacubitril/Valsartan Brand 44 $66,980
Jardiance Empagliflozin Brand 15 $24,479
Eliquis Apixaban Brand 11 $12,684
Torsemide Generic 50 $1,335
Isosorbide Dinitrate Generic 23 $1,102
Bumetanide Generic 14 $980
Potassium Chloride Generic 39 $843
Carvedilol Generic 51 $578

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$6,538

Medicare's payments for the services billed

Medicare patients

56

Average age 76

Services billed

102

24 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Atrial fibrillation 75%
Ischemic heart disease 71%
Chronic kidney disease 71%
Arthritis 63%
Diabetes 61%
COPD 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAINUA
  • AstraZeneca Pharmaceuticals LP $211
$211 — —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $115
$115 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $85
$85 — —
VYNDAQEL
  • PFIZER INC. $54
$54 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record